ProCE Banner Activity

CME

Key Studies in Melanoma: Independent Conference Coverage of the 2022 Society for Melanoma Research Annual Congress

Text Module

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.

Share

Faculty

Michael A. Davies

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for global physicians and other healthcare professionals who care for patients with melanoma.

Program Learning Goal

The goal of this activity is to improve the understanding of healthcare professionals globally on recent practice-changing clinical data on the treatment of patients with melanoma.

Learning Objectives

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with cancer
  • Evaluate new data on novel agents and combination therapeutic approaches for patients with melanoma
  • Appraise how new trial findings might affect the treatment of melanoma clinical practice in the future

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Michael A. Davies, MD, PhD: consultant/advisor/speaker: ABM Therapeutics, Bristol-Myers Squibb, Eisai, Iovance, Novartis, Pfizer, Roche/Genentech; researcher: ABM Therapeutics, Lead Pharma.

Jeffrey S. Weber, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Incyte, IoBio, Iovance, Merck, Moderna, Pfizer, Regeneron.

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose.

Faculty Disclosure

Primary Author

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

Michael A. Davies, MD, PhD: consultant/advisor/speaker: ABM Therapeutics, Bristol-Myers Squibb, Eisai, Iovance, Novartis, Pfizer, Roche/Genentech; researcher: ABM Therapeutics, Lead Pharma.

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Jeffrey S. Weber, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Incyte, IoBio, Iovance, Merck, Moderna, Pfizer, Regeneron.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 19, 2022, through December 18, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.